The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-02
DOI
10.1007/s10637-020-00934-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
- (2019) Rachael R. Schulte et al. MOLECULAR PHARMACOLOGY
- Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer
- (2019) Xiaoxue Zhang et al. DRUG DELIVERY
- Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer
- (2019) Amerigo Pagoto et al. MOLECULAR IMAGING AND BIOLOGY
- In vitro Cell Migration, Invasion, and Adhesion Assays: From Cell Imaging to Data Analysis
- (2019) Jordi Pijuan et al. Frontiers in Cell and Developmental Biology
- Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible
- (2019) Yu Zheng et al. BIOMEDICINE & PHARMACOTHERAPY
- Hyaluronic acid formulation of near infrared fluorophores optimizes surgical imaging in a prostate tumor xenograft
- (2018) Joshua J. Souchek et al. Acta Biomaterialia
- Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
- (2018) George E. Duran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy
- (2018) Zhen Fan et al. Nature Communications
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Design, Synthesis, and in Vitro and in Vivo Evaluation of High Affinity and Specificity Near-Infrared Fluorescent Bombesin Antagonists for Tumor Imaging
- (2018) Hang Xu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
- (2018) William T. Lowrance et al. JOURNAL OF UROLOGY
- Novel α 2 β 1 Integrin-Targeted Peptide Probes for Prostate Cancer Imaging
- (2018) Chiun-Wei Huang et al. Molecular Imaging
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
- (2017) Stéphane Oudard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy
- (2016) Xiaomin Yi et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
- (2016) Howard I. Scher et al. JAMA Oncology
- Optical innovations in surgery
- (2015) E. de Boer et al. BRITISH JOURNAL OF SURGERY
- Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer
- (2015) S. K. Martin et al. CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
- (2015) E. David Crawford et al. JOURNAL OF UROLOGY
- Sequencing of agents in castration-resistant prostate cancer
- (2015) David Lorente et al. LANCET ONCOLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Near-Infrared Emitting Fluorescent BODIPY Nanovesicles for in Vivo Molecular Imaging and Drug Delivery
- (2014) Li Quan et al. ACS Applied Materials & Interfaces
- Mechanisms of Resistance to Cabazitaxel
- (2014) G. E. Duran et al. MOLECULAR CANCER THERAPEUTICS
- The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
- (2014) Cynthia C. T. Sprenger et al. Hormones & Cancer
- IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy
- (2013) Caixia Yue et al. BIOMATERIALS
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
- (2013) Christian Thomas et al. MOLECULAR CANCER THERAPEUTICS
- The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer
- (2011) Amanda Obaidat et al. Annual Review of Pharmacology and Toxicology
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging
- (2010) Chao Zhang et al. BIOMATERIALS
- A targeted low molecular weight near-infrared fluorescent probe for prostate cancer
- (2010) Tiancheng Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now